Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour...

Area of Science:

• Oncology
• Molecular Biology
• Signal Transduction

Background:

• The c-MET receptor tyrosine kinase is frequently dysregulated in solid tumors, including small cell lung cancer (SCLC).
• Aberrant c-MET signaling contributes to tumor growth, invasion, and metastasis.
• Understanding the downstream signaling network of c-MET in SCLC is crucial for developing targeted therapies.

Purpose of the Study:

• To identify novel c-MET/hepatocyte growth factor (HGF) signaling intermediates in SCLC using a global proteomics approach.
• To investigate the role of c-MET activation in SCLC tumor progression and invasion.
• To evaluate c-MET as a therapeutic target in SCLC.

Main Methods:

• Utilized a global proteomics phosphoantibody array to profile c-MET/HGF signaling in NCI-H69 SCLC cells.
• Performed phosphoantibody-based immunohistochemical analysis on SCLC tumor tissue and microarrays.
• Investigated the effects of c-MET inhibition using small interfering RNA (siRNA) and the c-MET inhibitor SU11274.

Main Results:

• Hepatocyte growth factor (HGF) induced phosphorylation of c-MET and downstream effectors including paxillin, ERK1/2, MEK1/2, RB1, JNK, STAT3, FAK, p38alpha-MAPK, and AKT1.
• HGF also modulated phosphorylation of adducin-alpha, adducin-gamma, and CREB.
• Conversely, HGF inhibited phosphorylation in protein kinase C (PKC), protein kinase R (PKR), and CDK1.
• c-MET activation was observed at the invasive front of SCLC tumors, involving FAK and AKT signaling.
• Inhibition of c-MET reduced phosphorylation of downstream targets like AKT, S6 kinase, and ERK1/2.

Conclusions:

• c-MET plays a significant role in SCLC biology, particularly in tumor progression and invasion via FAK and AKT pathways.
• Targeting c-MET represents a viable therapeutic strategy for SCLC.
• Further investigation into c-MET-mediated invasion and metastasis signaling is warranted.